导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.99% | 2811/4773 |
| 近一周 | -2.57% | 2574/5462 |
| 近一月 | -3.31% | 1682/5421 |
| 近一季 | -11.20% | 3676/5209 |
| 近半年 | -9.99% | 3577/4920 |
| 近一年 | 0.33% | 2591/4366 |
| 近两年 | 74.40% | 893/2954 |
| 近三年 | 37.45% | 786/2253 |
| 成立以来 | 122.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.44% 1274/4961 |
12.99% 2083/5312 |
- - |
- - |
| 2025 | 34.98% 1010/4813 |
6.50% 622/3635 |
4.88% 690/4076 |
21.13% 1845/4524 |
-0.23% 2429/4813 |
| 2024 | 6.46% 1754/3463 |
-5.59% 1929/2808 |
-5.63% 1764/3014 |
16.17% 1516/3129 |
2.86% 882/3463 |
| 2023 | 0.62% 400/2656 |
11.98% 320/2280 |
-1.25% 462/2385 |
-6.29% 1465/2515 |
-2.89% 552/2655 |
| 2022 | -13.36% 326/2207 |
-12.33% 602/1919 |
7.14% 524/2016 |
-10.71% 442/2113 |
3.31% 724/2208 |
| 2021 | 27.72% 87/1822 |
2.29% 222/1255 |
9.38% 554/1330 |
5.32% 279/1466 |
8.38% 156/1822 |
| 2020 | 37.21% 383/1250 |
1.41% 144/1028 |
24.29% 175/1067 |
8.37% 719/1164 |
0.46% 1057/1184 |
| 2019 | 42.18% 220/1092 |
28.76% 295/739 |
-3.37% 387/788 |
3.75% 234/850 |
10.14% 158/918 |
| 2018 | -29.54% 455/834 |
- - |
-13.25% 439/631 |
-8.98% 500/660 |
-10.54% 204/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商中证1000指数增强C VS. 长安沪深300非周期A(740101) |